Osimertinib for Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma

J Thorac Oncol. 2017 Oct;12(10):e167-e169. doi: 10.1016/j.jtho.2017.06.071.

Authors

Naoyuki Okabe¹, Hironori Takagi¹, Hayato Mine², Satoshi Fukai², Hiroyuki Minemura³, Hiroyuki Suzuki⁴

Affiliations

¹ Respiratory Surgery, Takeda General Hospital, Aizuwakamatsu, Japan.
² Initial Training Physicians, Takeda General Hospital, Aizuwakamatsu, Japan.
³ Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
⁴ Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan. Electronic address: hiro@fmu.ac.jp.

PMID: 28939151
DOI: 10.1016/j.jtho.2017.06.071

No abstract available

Publication types

Letter

MeSH terms

Acrylamides
Aged
Aniline Compounds
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / pathology
ErbB Receptors / genetics*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Mutation
Piperazines / pharmacology
Piperazines / therapeutic use*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*

Substances

Acrylamides
Aniline Compounds
Piperazines
Protein Kinase Inhibitors
osimertinib
ErbB Receptors